Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
PYXS Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 11, 2026
Report Source: 2026 1st Quarter Report
Pyxis Oncology Inc. Stock Analysis PYXS
United States Health Care Micro Cap Report: Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2021-10-08. The firm is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Read More Pyxis Oncology Inc (PYXS) Chart
Key Statistics of Pyxis Oncology Inc (PYXS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$2.08Volume
408.03KP/E Ratio (TTM)
-52 Week Range
Market Cap
122.91MAvg. Volume
483.28KDividend Yield
-Financial Metrics & Statements of Pyxis Oncology Inc (PYXS)
FAQ's for Pyxis Oncology Inc (PYXS)
- According to Musaffa’s Shariah screening methodology, Pyxis Oncology Inc (PYXS) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Pyxis Oncology Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Pyxis Oncology Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Pyxis Oncology Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Pyxis Oncology Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Pyxis Oncology Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.